While NewAmsterdam Pharma Company NV has underperformed by -1.09%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NAMS rose by 83.45%, with highs and lows ranging from $26.35 to $8.90, whereas the simple moving average fell by -7.15% in the last 200 days.
On May 15, 2024, TD Cowen started tracking NewAmsterdam Pharma Company NV (NASDAQ: NAMS) recommending Buy. A report published by Scotiabank on March 14, 2024, Initiated its previous ‘Sector Outperform’ rating for NAMS. Guggenheim also rated NAMS shares as ‘Buy’, setting a target price of $30 on the company’s shares in an initiating report dated January 18, 2024. Piper Sandler Initiated an Overweight rating on January 16, 2024, and assigned a price target of $37. RBC Capital Mkts initiated its ‘Outperform’ rating for NAMS, as published in its report on October 30, 2023.
Analysis of NewAmsterdam Pharma Company NV (NAMS)
NewAmsterdam Pharma Company NV’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. Taking into account the quick ratio of the company, currently set at 10.61, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and NAMS is registering an average volume of 417.09K. On a monthly basis, the volatility of the stock is set at 6.47%, whereas on a weekly basis, it is put at 6.69%, with a loss of -13.12% over the past seven days. Furthermore, long-term investors anticipate a median target price of $37.38, showing growth from the present price of $18.07, which can serve as yet another indication of whether NAMS is worth investing in or should be passed over.
How Do You Analyze NewAmsterdam Pharma Company NV Shares?
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 53.55%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 40.63% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
NAMS shares are owned by institutional investors to the tune of 40.63% at present.
